FLT3 and acute myeloid leukemia: The observation that a majority of patients treated with a potent FLT3 inhibitor who developed acquired resistance harbored newly detected secondary kinase domain mutations in FLT3-ITD3 definitively validating FLT3-ITD as a therapeutic target in human AML.